RCA HGB-208 Pushback Seen as 'Modest Stumble', Roth Capital Says

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. CRWD
2. REGN
3. LITE
4. AAPL
5. ABBV
6. MRVL
7. CL
8. LYB
9. TFII
10. ORCL

Go back to RCA HGB-208 Pushback Seen as 'Modest Stumble', Roth Capital Says

bluebird bio Completes NIH RAC Review of HGB-208 Pediatric Study Protocol

June 9, 2015 6:21 PM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, announced today the completion of the National Institutes of Health (NIH) Recombinant DNA Advisory Committees (RAC) public review of the HGB-208 pediatric study protocol for bluebird bios LentiGlobin BB305 product candidate in beta-thalassemia major. The RAC recommendation was to delay initiation of the study in the United States for one to two years. This recommendation has no effect on the HGB-207 protocol plan.

... More